-
-
-
-
-
-
-
Almirall Continues Its Positive Trajectory in Q1 2026 in Line With Expectations – Led by 19.3% YoY Growth of Its European Dermatology Business
-
-
-
-
-
-
-
Almonty Industries Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business
-
-
-
-
-
-
-
Almirall achieves Core Net Sales growth of 5.1% to 436.6 MM Euros in H1
-
-
-
-
-
-
-
Almirall demonstrates resilient performance year to date despite COVID-19 impacts
1,216,204 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

